---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-128491"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:43:15.579858+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BMS terminates collaboration with Century Therapeutics without cause; effective March 12, 2025

## Summary
- BMS notified Century on Dec 12, 2024 of termination of the 2022 Research, Collaboration and License Agreement.
- Termination covers all iPSC-derived NK and gamma delta T cell programs for hematologic malignancies.
- Century will evaluate opportunities in AML and multiple myeloma under ongoing strategic review of pre-clinical pipeline.
- Both parties will cooperate on termination provisions; no financial details of termination disclosed.

## SEC filing metadata
- accession: 0001104659-24-128491
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465924128491/0001104659-24-128491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465924128491/tm2431062d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-128491
- JSON: https://secwatch.observer/filing/0001104659-24-128491.json
- Plain text: https://secwatch.observer/filing/0001104659-24-128491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.